CD4‑targeted ADC
Autoimmune diseases
PreclinicalActive
Key Facts
About TaiMed Biologics
TaiMed Biologics combines CD4‑targeted biologics with CDMO services to address HIV and autoimmune markets.
View full company profileTherapeutic Areas
Other Autoimmune diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Humira (Adalimumab) Biosimilar | NeuClone | Early Preclinical |
| HBM7020 | Harbour BioMed | Discovery |
| R2006 | Harbour BioMed | Discovery |
| R7027 | Harbour BioMed | Discovery |
| ImmCelz™ Platform | Creative Medical Technology Holdings | Preclinical |
| Gavocabtagene autoleucel | Astellas | Phase 1/2 |
| HCB206 | HanchorBio | Preclinical |
| miR-124 Activator | Formation Bio | Phase 2 |
| Autologous Cell Therapy Collaboration | Lupagen | Preclinical |
| Autoimmune Diagnostics Leadership Initiative | Vibrant America Clinical Laboratory | Commercial |
| I&I Portfolio | Third Arc Bio | Pre-clinical |
| Undisclosed Platform Programs | Zag Bio | Preclinical |